BioXcel Therapeutics (BTAI) Asset Utilization Ratio (2022 - 2026)

BioXcel Therapeutics' Asset Utilization Ratio history runs 5 years deep, the most recent figure standing at 0.02 for Q1 2026.

• On a quarterly basis, Asset Utilization Ratio fell 64.23% year-over-year to 0.02 in Q1 2026; TTM through Mar 2026 was 0.02, a 64.23% decrease from a year earlier, with the FY2025 full-year figure at 0.02, down 61.87% from the prior year.
• Asset Utilization Ratio rose to 0.02 in Q1 2026 per BTAI's latest filing, from 0.01 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.05 in Q4 2024 and bottomed at 0.0 in Q3 2022.
• The 5-year median for Asset Utilization Ratio is 0.02 (2026), against an average of 0.02.
• Across the five-year window, Asset Utilization Ratio soared 1758.22% in 2023 and plunged 72.45% in 2025, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.0 in 2022, then surged by 852.32% to 0.02 in 2023, then jumped by 227.82% to 0.05 in 2024, then plunged by 72.45% to 0.01 in 2025, then climbed by 20.37% to 0.02 in 2026.
• Per Business Quant, the three latest BTAI Asset Utilization Ratio figures stand at 0.02 (Q1 2026), 0.01 (Q4 2025), and 0.02 (Q3 2025).